{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:39:38Z","timestamp":1787801978163,"version":"build-2784847793"},"reference-count":37,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"12","license":[{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Innovative Research Groups of the National Natural Science Foundation of China","award":["81621001"],"award-info":[{"award-number":["81621001"]}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2017YFA0104500"],"award-info":[{"award-number":["2017YFA0104500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930004"],"award-info":[{"award-number":["81930004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health\u2010related quality of life (HR\u2010QoL) after total therapy, which included allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT), and prophylactic donor lymphocyte infusion (DLI) in the early phase after transplantation, followed by multiple measurable residual disease (MRD) and graft\u2010versus\u2010host disease (GvHD)\u2010guided DLIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">Consecutive patients who had refractory or relapsed AML and had received non\u2010T\u2010cell\u2010depleted allo\u2010HSCT at Peking University Institute of Hematology were included in the study. If the patients achieved complete remission at 30 days after transplantation and had no evidence of relapse, severe infection, organ failure, and active GvHD at the time of planned DLI, prophylactic DLI was administered at 30 days after transplantation for human leukocyte antigen (HLA)\u2010matched related HSCT or at 45\u201060 days after transplantation for haploidentical or unrelated HSCT. Subsequently, multiple DLIs were administered based on MRD results and whether they developed GvHD after transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">A total of 105 patients were eligible. Eighty\u2010seven patients received prophylactic DLI (group B), while 18 did not receive prophylactic DLI (group A). Among 105 patients, the cumulative incidence of grade 2\u20104 acute GvHD and chronic GvHD was 40.6% (95% confidence interval [CI] = 30.6%\u201050.6%) and 73.3% (95% CI = 67.4%\u201079.2%), respectively. The cumulative incidence of relapse (CIR), transplant\u2010related mortality (TRM), and leukemia\u2010free survival (LFS) at 5 years after transplantation were 31.5% (95% CI = 21.9%\u201041.1%), 22.1% (95% CI = 11.3%\u201032.9%), and 46.4% (95% CI = 36.8%\u201056.0%), respectively. In group B, the CIR, TRM, and LFS at 5 years after transplantation were 27.6% (95% CI = 17.6%\u201037.6%), 21.6% (95% CI = 11.2%\u201032.0%), and 50.8% (95% CI = 40.0%\u201061.6%), respectively. At the end of follow\u2010up, 48 patients survived, and more than 90% of survivors had satisfactory recoveries of HR\u2010QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Our study indicated that total therapy is not only associated with decreased CIR, comparable TRM, and better long\u2010term LFS, but also with satisfactory HR\u2010QoL for refractory or relapsed AML, compared with those of standard of care therapy reported previously. Therefore, total therapy may be an optimized therapeutic strategy for refractory or relapsed AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.12376","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T02:44:33Z","timestamp":1666579473000},"page":"1387-1402","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long\u2010term clinical outcomes and health\u2010related quality of life assessment"],"prefix":"10.34133","volume":"42","author":[{"given":"Chen\u2010hua","family":"Yan","sequence":"first","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-7465","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010qian","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010fei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7945","authenticated-orcid":false,"given":"Xiao\u2010dong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng\u2010rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan\u2010yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting\u2010ting","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan\u2010ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai\u2010yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao\u2010jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University Peoples Hospital","place":["Beijing, P. R. China"]},{"name":"Peking University Institute of Hematology","place":["Beijing, P. R. China"]},{"name":"National Clinical Research Center for Hematologic Disease","place":["Beijing, P. R. China"]},{"name":"Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation","place":["Beijing, P. R. China"]},{"name":"Peking\u2010Tsinghua Center for Life Science","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"issue":"9","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems DA","year":"2005","unstructured":"Breems DA, Van Putten WLJ, Huijgens PC, Ossenkoppele GJ, Verhoef GEJ, Verdonck LF, et\u00a0al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23((9)):1969\u201378.","journal-title":"J Clin Oncol"},{"issue":"18","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk RF","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L, et\u00a0al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358((18)):1909\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cac2.12094","article-title":"Analysis of the Global Burden of Disease study highlights the trends in death and disability\u2010adjusted life years of leukemia from 1990 to 2017","volume":"40","author":"Ou Z","year":"2020","unstructured":"Ou Z, Yu D, Liang Y, He W, Li Y, Zhang M, et\u00a0al. Analysis of the Global Burden of Disease study highlights the trends in death and disability\u2010adjusted life years of leukemia from 1990 to 2017. Cancer Commun (Lond). 2020;40((11)):598\u2013610.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.26000","article-title":"The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)","volume":"96","author":"Poiani M","year":"2021","unstructured":"Poiani M, Labopin M, Battipaglia G, Beelen DW, Tischer J, Finke J, et\u00a0al. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed\/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96((1)):40\u201350.","journal-title":"Am J Hematol"},{"issue":"1","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","article-title":"Fludarabine\u2010treosulfan compared to thiotepa\u2010busulfan\u2010fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"12","author":"Saraceni F","year":"2019","unstructured":"Saraceni F, Labopin M, Brecht A, Kr\u00f6ger N, Eder M, Tischer J, et\u00a0al. Fludarabine\u2010treosulfan compared to thiotepa\u2010busulfan\u2010fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol. 2019;12((1)):44.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","article-title":"FLAMSA\u2010Based Reduced\u2010Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed\/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Rodr\u00edguez\u2010Arbol\u00ed E","year":"2020","unstructured":"Rodr\u00edguez\u2010Arbol\u00ed E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et\u00a0al. FLAMSA\u2010Based Reduced\u2010Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed\/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020;26((11)):2165\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot E","year":"2019","unstructured":"Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et\u00a0al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019;104((3)):524\u201332.","journal-title":"Haematologica"},{"issue":"1","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-017-0498-8","article-title":"Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Brissot E","year":"2017","unstructured":"Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, et\u00a0al. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10((1)):130.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.bbmt.2006.07.014","article-title":"Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation","volume":"12","author":"Or R","year":"2006","unstructured":"Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, et\u00a0al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant. 2006;12((2)):1295\u20131301.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1399-0012.2012.01618.x","article-title":"Modified donor lymphocyte infusion\u2010associated acute graft\u2010versus\u2010host disease after haploidentical T\u2010cell\u2010replete hematopoietic stem cell transplantation: incidence and risk factors","volume":"26","author":"Yan CH","year":"2012","unstructured":"Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y, et\u00a0al. Modified donor lymphocyte infusion\u2010associated acute graft\u2010versus\u2010host disease after haploidentical T\u2010cell\u2010replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant. 2012;26((6)):868\u201376.","journal-title":"Clin Transplant"},{"issue":"5","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/bmt.2009.26","article-title":"Administration of short\u2010term immunosuppressive agents after DLI reduces the incidence of DLI\u2010associated acute GVHD without influencing the GVL effect","volume":"44","author":"Huang XJ","year":"2009","unstructured":"Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, et\u00a0al. Administration of short\u2010term immunosuppressive agents after DLI reduces the incidence of DLI\u2010associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant. 2009;44((5)):309\u201316.","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.3760\/cma.j.issn.0366-6999.20141481","article-title":"Immunosuppression for 6\u20108 weeks after modified donor lymphocyte infusion reduced acute graft\u2010versus\u2010host disease without influencing graft\u2010versus\u2010leukemia effect in haploidentical transplant","volume":"127","author":"Yan CH","year":"2014","unstructured":"Yan CH, Xu LP, Liu DH, Chen H, Wang Y, Liu KY, et\u00a0al. Immunosuppression for 6\u20108 weeks after modified donor lymphocyte infusion reduced acute graft\u2010versus\u2010host disease without influencing graft\u2010versus\u2010leukemia effect in haploidentical transplant. Chin Med J (Engl). 2014;127((20)):3602\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","article-title":"Prevention of relapse using DLI can increase survival following HLA\u2010identical transplantation in patients with advanced\u2010stage acute leukemia: a multi\u2010center study","volume":"26","author":"Wang Y","year":"2012","unstructured":"Wang Y, Liu DH, Fan ZP, Sun J, Wu XJ, Ma X, et\u00a0al. Prevention of relapse using DLI can increase survival following HLA\u2010identical transplantation in patients with advanced\u2010stage acute leukemia: a multi\u2010center study. Clin Transplant. 2012;26((4)):635\u201343.","journal-title":"Clin Transplant"},{"issue":"8","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/bmt.2011.213","article-title":"Prevention of relapse using granulocyte CSF\u2010primed PBPCs following HLA\u2010mismatched\/haploidentical, T\u2010cell\u2010replete hematopoietic SCT in patients with advanced\u2010stage acute leukemia: a retrospective risk\u2010factor analysis","volume":"47","author":"Wang Y","year":"2012","unstructured":"Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, et\u00a0al. Prevention of relapse using granulocyte CSF\u2010primed PBPCs following HLA\u2010mismatched\/haploidentical, T\u2010cell\u2010replete hematopoietic SCT in patients with advanced\u2010stage acute leukemia: a retrospective risk\u2010factor analysis. Bone Marrow Transplant. 2012;47((8)):1099\u20131104.","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","article-title":"Risk stratification\u2010directed donor lymphocyte infusion could reduce relapse of standard\u2010risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Yan CH","year":"2012","unstructured":"Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et\u00a0al. Risk stratification\u2010directed donor lymphocyte infusion could reduce relapse of standard\u2010risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119 ((14)):3256\u201362.","journal-title":"Blood"},{"issue":"8","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","article-title":"Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft\u2010versus\u2010Host Disease\u2010Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory\/Relapsed Acute Leukemia","volume":"23","author":"Yan CH","year":"2017","unstructured":"Yan CH, Liu QF, Wu DP, Zhang X, Xu LP, Zhang XH, et\u00a0al. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft\u2010versus\u2010Host Disease\u2010Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory\/Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2017;23((8)):1311\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA\u2010mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA\u2010identical sibling transplantation","volume":"107","author":"Lu DP","year":"2006","unstructured":"Lu DP, Dong LJ, Wu T, Huang XJ, Zhang MJ, Han W, et\u00a0al. Conditioning including antithymocyte globulin followed by unmanipulated HLA\u2010mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA\u2010identical sibling transplantation. Blood. 2006;107((8)):3065\u201373.","journal-title":"Blood"},{"issue":"1","key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","article-title":"Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre\u2010transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis","volume":"10","author":"Chang YJ","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et\u00a0al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre\u2010transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10((1)):134.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao XS","year":"2013","unstructured":"Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY, et\u00a0al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013; 92((8)):1111\u20109.","journal-title":"Ann Hematol"},{"issue":"17","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient\u2010reported quality of life is associated with severity of chronic graft\u2010versus\u2010host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala J","year":"2011","unstructured":"Pidala J, Kurland B, Chai XY, Majhail N, Weisdorf DJ, Pavletic S, e al. Patient\u2010reported quality of life is associated with severity of chronic graft\u2010versus\u2010host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117((17)):4651\u20137.","journal-title":"Blood"},{"issue":"17","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone marrow transplantation","volume":"92","author":"Tomas ED","year":"1975","unstructured":"Tomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et\u00a0al. Bone marrow transplantation. N Engl J Med. 1975;92((17)):895\u2013902.","journal-title":"N Engl J Med"},{"issue":"12","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft\u2010versus\u2010host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich AH","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et\u00a0al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft\u2010versus\u2010host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11((12)):945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbmt.2012.10.002","article-title":"Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation","volume":"19","author":"Wang Y","year":"2013","unstructured":"Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et\u00a0al. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19((2)):283\u201390.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbmt.2016.11.002","article-title":"Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate\u2010 or High\u2010Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"23","author":"Malard F","year":"2017","unstructured":"Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, et\u00a0al. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate\u2010 or High\u2010Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23((2)):278\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.30536","article-title":"Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission","volume":"123","author":"Weisdorf DJ","year":"2017","unstructured":"Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, et\u00a0al. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017;123((11)):2025\u201334.","journal-title":"Cancer"},{"issue":"4","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.bmt.1702519","article-title":"Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience","volume":"26","author":"Sierra J","year":"2000","unstructured":"Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, et\u00a0al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26((4)):397\u2013404.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bmt.2014.223","article-title":"Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome","volume":"50","author":"Mo XD","year":"2015","unstructured":"Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, et\u00a0al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant. 2015;50((1)):127\u201333.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"839.e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or Preemptive Low\u2010Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High\u2010Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome","volume":"27","author":"Guillaume T","year":"2021","unstructured":"Guillaume T, Th\u00e9pot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, et\u00a0al. Prophylactic or Preemptive Low\u2010Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High\u2010Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplant Cell Ther. 2021;27((10)):839.e1\u2010839.e6.","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial","volume":"100","author":"Amit O","year":"2021","unstructured":"Amit O, On YB, Perez G, Shargian\u2010Alon L, Yeshurun M, Ram R. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial. Ann Hemato. 2021;100((3)):817\u201324.","journal-title":"Ann Hemato"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-020-00178-y","article-title":"Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells","volume":"9","author":"Kwon YR","year":"2020","unstructured":"Kwon YR, Kim HJ, Sohn MJ, Lim JY, Park KS, Lee S et\u00a0al. Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells. Exp Hematol Oncol. 2020;9:22.","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.bbmt.2016.07.016","article-title":"Improved Outcome of Refractory\/Relapsed Acute Myeloid Leukemia after Post\u2010Transplantation Cyclophosphamide\u2010Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony\u2010Stimulating Factor\u2010Mobilized Donor Lymphocyte Infusions","volume":"22","author":"Jaiswal SR","year":"2016","unstructured":"Jaiswal SR, Zaman S, Chakrabarti A, Sen S, Mukherjee S, Bhargava S, et\u00a0al. Improved Outcome of Refractory\/Relapsed Acute Myeloid Leukemia after Post\u2010Transplantation Cyclophosphamide\u2010Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony\u2010Stimulating Factor\u2010Mobilized Donor Lymphocyte Infusions. Biol Blood Marrow Transplant. 2016;22((10)):1867\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced\u2010intensity conditioning for allogeneic stem\u2010cell transplantation, and prophylactic donor lymphocyte transfusion in high\u2010risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid C","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced\u2010intensity conditioning for allogeneic stem\u2010cell transplantation, and prophylactic donor lymphocyte transfusion in high\u2010risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23((24)):5675\u201387.","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1158\/1078-0432.CCR-17-3622","article-title":"Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low\u2010Dose TBI\u2010Based Regimen","volume":"24","author":"Baron F","year":"2018","unstructured":"Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, et\u00a0al. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low\u2010Dose TBI\u2010Based Regimen. Clin Cancer Res. 2018;24((12)):2794\u20132803.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"e_1_3_2_35_2","first-page":"1517","article-title":"In vivo induction of T\u2010cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony\u2010stimulating factor","volume":"89","author":"Huang XJ","year":"2004","unstructured":"Huang XJ, Chang YJ, Zhao XY. In vivo induction of T\u2010cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony\u2010stimulating factor. Haematologica. 2004;89((12)):1517\u201324.","journal-title":"Haematologica"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2006.10.002"},{"issue":"11","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1172\/JCI25249","article-title":"NKT cell\u2010 dependent leukemia eradication following stem cell mobilization with potent G\u2010CSF analogs","volume":"115","author":"Morris ES","year":"2005","unstructured":"Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don ALJ, et\u00a0al. NKT cell\u2010 dependent leukemia eradication following stem cell mobilization with potent G\u2010CSF analogs. J Clin Invest. 2005;115((11)):3093\u20133103.","journal-title":"J Clin Invest"},{"issue":"8","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.bbmt.2020.04.020","article-title":"Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia","volume":"26","author":"Wright R","year":"2020","unstructured":"Wright R, Oremek M, Davies D, Kewley C, Singh A, Taitt N, et\u00a0al. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2020;26((8)):1527\u201333.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cac2.12376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cac2.12376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:52:14Z","timestamp":1773823934000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/cac2.12376"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12376","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,23]]},"assertion":[{"value":"2022-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}